Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Nucleic Acids Res ; 44(22): 11013-11023, 2016 12 15.
Article in English | MEDLINE | ID: mdl-27789698

ABSTRACT

The MYC proto-oncogene is upregulated, often at the transcriptional level, in ∼80% of all cancers. MYC's promoter is governed by a higher order G-quadruplex (G4) structure in the NHE III1 region. Under a variety of conditions, multiple isoforms have been described to form from the first four continuous guanine runs (G41-4) predominating under the physiologically relevant supercoiled conditions. In the current study, short oligonucleotides complementing the 5'- and 3'-regions flanking the G4 have been connected by an abasic linker to form G4 clamps, varying both linker length and G4 isoform being targeted. Clamp A with an 18 Šlinker was found to have marked affinity for its target isomer (G41-4) over the other major structures (G42-5 and G41-5, recognized by clamps B and C, respectively), and to be able to shift equilibrating DNA to foster greater G4 formation. In addition, clamp A, but not B or C, is able to modulate MYC promoter activity with a significant and dose-dependent effect on transcription driven by the Del4 plasmid. This linked clamp-mediated approach to G4 recognition represents a novel therapeutic mechanism with specificity for an individual promoter structure, amenable to a large array of promoters.


Subject(s)
G-Quadruplexes , Oligonucleotides/chemistry , Promoter Regions, Genetic , Proto-Oncogene Proteins c-myc/genetics , Base Sequence , Gene Expression , Gene Silencing , Genes, Reporter , HEK293 Cells , Humans , Luciferases, Firefly/biosynthesis , Luciferases, Firefly/genetics , Oligonucleotides/genetics , Proto-Oncogene Mas
2.
Biochim Biophys Acta ; 1859(2): 235-45, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26597160

ABSTRACT

kRAS is one of the most prevalent oncogenic aberrations. It is either upregulated or mutationally activated in a multitude of cancers, including pancreatic, lung, and colon cancers. While a significant effort has been made to develop drugs that target kRAS, their clinical activity has been disappointing due to a variety of mechanistic hurdles. The presented works describe a novel mechanism and molecular target to downregulate kRAS expression--a previously undescribed G-quadruplex (G4) secondary structure within the proximal promoter acting as a transcriptional silencer. There are three distinct guanine-rich regions within the core kRAS promoter, including a previously examined region (G4near). Of these regions, the most distal region does not form an inducible and stable structure, whereas the two more proximal regions (termed near and mid) do form strong G4s. G4near is predominantly a tri-stacked structure with a discontinuous guanine run incorporated; G4mid consists of seven distinct runs of continuous guanines and forms numerous competing isoforms, including a stable three-tetrad stacked mixed parallel and antiparallel loop structures with longer loops of up to 10 nucleotides. Comprehensive analysis of the regulation of transcription by higher order structures has revealed that the guanine-rich region in the middle of the core promoter, termed G4mid, is a stronger repressor of promoter activity than G4near. Using the extensive guanine-rich region of the kRAS core promoter, and particularly the G4mid structure, as the primary target, future drug discovery programs will have potential to develop a potent, specifically targeted small molecule to be used in the treatment of pancreatic, ovarian, lung, and colon cancers.


Subject(s)
G-Quadruplexes , Neoplasms/genetics , Promoter Regions, Genetic , Proto-Oncogene Proteins p21(ras)/genetics , Circular Dichroism , Gene Expression Regulation, Neoplastic , Humans , Models, Molecular , Mutation , Neoplasms/drug therapy , Neoplasms/pathology , Nucleic Acid Conformation , Proto-Oncogene Proteins p21(ras)/chemistry
3.
Molecules ; 18(12): 15019-34, 2013 Dec 05.
Article in English | MEDLINE | ID: mdl-24317528

ABSTRACT

ADAM-15, with known zymogen, secretase, and disintegrin activities, is a catalytically active member of the ADAM family normally expressed in early embryonic development and aberrantly expressed in various cancers, including breast, prostate and lung. ADAM-15 promotes extracellular shedding of E-cadherin, a soluble ligand for the HER2/neu receptor, leading to activation, increased motility, and proliferation. Targeted downregulation of both ADAM-15 and HER2/neu function synergistically kills breast cancer cells, but to date there are no therapeutic options for decreasing ADAM-15 function or expression. In this vein, we have examined a unique string of guanine-rich DNA within the critical core promoter of ADAM-15. This region of DNA consists of seven contiguous runs of three or more consecutive guanines, which, under superhelical stress, can relax from duplex DNA to form an intrastrand secondary G-quadruplex (G4) structure. Using biophysical and biological techniques, we have examined the G4 formation within the entire and various truncated regions of the ADAM-15 promoter, and demonstrate strong intrastrand G4 formation serving to function as a biological silencer element. Characterization of the predominant G4 species formed within the ADAM-15 promoter will allow for specific drug targeting and stabilization, and the further development of novel, targeted therapeutics.


Subject(s)
ADAM Proteins/chemistry , ADAM Proteins/genetics , Breast Neoplasms/genetics , G-Quadruplexes , Membrane Proteins/chemistry , Membrane Proteins/genetics , Promoter Regions, Genetic , Base Sequence , Cell Line , Circular Dichroism , Female , Gene Silencing , Humans , Mutation , Transcription, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...